Login to Your Account

Omthera Shoots for Expanded Epanova Label

By Catherine Shaffer

Tuesday, August 16, 2011
Omthera Pharmaceuticals Inc. enrolled its first patient in a new Phase III trial designed to expand the label of its investigational therapy for high triglycerides, Epanova. Epanova is a purified mixture of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) that Omthera previously tested in two large, Phase III trials in Crohn's disease patients.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription